Q1 2021 13F Holders as of 3/31/2021
-
Type / Class
-
Equity / Common Stock, par value $0.01 per share
-
Shares outstanding
-
93.1M
-
Number of holders
-
194
-
Total 13F shares, excl. options
-
73.9M
-
Shares change
-
-1.26M
-
Total reported value, excl. options
-
$2.25B
-
Value change
-
-$33.4M
-
Put/Call ratio
-
0.68
-
Number of buys
-
82
-
Number of sells
-
-92
-
Price
-
$30.45
Significant Holders of MYRIAD GENETICS INC - Common Stock, par value $0.01 per share (MYGN) as of Q1 2021
228 filings reported holding MYGN - MYRIAD GENETICS INC - Common Stock, par value $0.01 per share as of Q1 2021.
MYRIAD GENETICS INC - Common Stock, par value $0.01 per share (MYGN) has 194 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 73.9M shares
of 93.1M outstanding shares and own 79.33% of the company stock.
Largest 10 shareholders include BlackRock Inc. (13.2M shares), VANGUARD GROUP INC (8.62M shares), EARNEST PARTNERS LLC (7.19M shares), STATE STREET CORP (4.03M shares), Camber Capital Management LP (3M shares), BANK OF AMERICA CORP /DE/ (2.75M shares), DIMENSIONAL FUND ADVISORS LP (2.73M shares), PFM Health Sciences, LP (2.72M shares), D. E. Shaw & Co., Inc. (2.66M shares), and GLENVIEW CAPITAL MANAGEMENT, LLC (2.57M shares).
This table shows the top 194 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.